# Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance

> **NCT01113619** · PHASE2 · COMPLETED · sponsor: **Ritter Pharmaceuticals, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Lactose Intolerance

## Interventions

- **DRUG:** RP-G28 or placebo
- **DRUG:** RP-G28 or placebo

## Key facts

- **NCT ID:** NCT01113619
- **Lead sponsor:** Ritter Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-10
- **Final completion:** 2011-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2011-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113619, "Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01113619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*